IPCALAB

Ipca Laboratories Share Price

₹1,501.90 +31.85 (2.17%)

31 Mar, 2025 10:18

SIP TrendupStart SIP in IPCALAB

Start SIP

Performance

  • Low
  • ₹1,421
  • High
  • ₹1,511
  • 52 Week Low
  • ₹1,052
  • 52 Week High
  • ₹1,756
  • Open Price₹1,461
  • Previous Close₹1,470
  • Volume325,369

Investment Returns

  • Over 1 Month + 9.73%
  • Over 3 Month -9.68%
  • Over 6 Month + 1.61%
  • Over 1 Year + 21.38%
SIP Lightning

Smart Investing Starts Here Start SIP with Ipca Laboratories for Steady Growth!

Invest Now

Ipca Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 52.2
  • PEG Ratio
  • 1.8
  • Market Cap Cr
  • 38,104
  • P/B Ratio
  • 5.7
  • Average True Range
  • 56.62
  • EPS
  • 31.24
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -12.84
  • RSI
  • 64.84
  • MFI
  • 78.9

Ipca Laboratories Financials

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,501.90
+ 31.85 (2.17%)
pointer
  • stock-down_img
  • Bearish Moving Average 2
  • stock-up_img
  • Bullish Moving Average 14
  • 20 Day
  • ₹1,409.74
  • 50 Day
  • ₹1,437.16
  • 100 Day
  • ₹1,462.30
  • 200 Day
  • ₹1,424.43

Resistance and Support

1477.7 Pivot Speed
  • R3 1,625.10
  • R2 1,567.90
  • R1 1,534.90
  • S1 1,444.70
  • S2 1,387.50
  • S3 1,354.50

What's your outlook on Ipca Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ipca Laboratories Ltd. is a global pharmaceutical company, producing over 350 formulations and 80 APIs. Operating in 120+ countries, it leads in therapeutic areas like pain, rheumatology, and antimalarials, with fully-automated facilities approved by global regulatory bodies.

Ipca Laboratories has an operating revenue of Rs. 8,725.91 Cr. on a trailing 12-month basis. An annual revenue growth of 23% is outstanding, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 9%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around 4% and 3% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 73 which is a FAIR score but needs to improve its earnings, a RS Rating of 79 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 47 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Ipca Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-13 Quarterly Results
2024-11-14 Quarterly Results & Interim Dividend
2024-09-30 Others
2024-08-13 Quarterly Results
2024-05-29 Audited Results & Final Dividend
Date Purpose Remarks
2024-11-25 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
View More
Date Purpose Remarks
2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

Ipca Laboratories F&O

Ipca Laboratories Shareholding Pattern

44.72%
29.63%
5.19%
11.06%
0%
6.88%
2.52%

About Ipca Laboratories

  • NSE Symbol
  • IPCALAB
  • BSE Symbol
  • 524494
  • Managing Director
  • Mr. Ajit Kumar Jain
  • ISIN
  • INE571A01038

Similar Stocks to Ipca Laboratories

Ipca Laboratories FAQs

Ipca Laboratories share price is ₹1,501 As on 31 March, 2025 | 10:04

The Market Cap of Ipca Laboratories is ₹38103.8 Cr As on 31 March, 2025 | 10:04

The P/E ratio of Ipca Laboratories is 52.2 As on 31 March, 2025 | 10:04

The PB ratio of Ipca Laboratories is 5.7 As on 31 March, 2025 | 10:04

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23